COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05738-4 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Sophie Thau und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zealand University Hospital, Roskilde, Denmark. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Sulfonamides, COVID-19, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Copenhagen University.
Abstract (Originalsprache)
Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a single-center study of 108 patients with small lymphocytic lymphoma or CLL treated with venetoclax. Primary outcome was 30-day COVID-19 mortality. Secondary outcomes included COVID-19 severity and hospitalization rate. Forty-eight (44%) patients had PCR-verified SARS-COV-2 between March 2020 and January 2023. Thirty-six patients (75%) presented with asymptomatic/mild COVID-19 and 12 (25%) with severe/critical disease. The hospitalization rate was 46% with a 30-day mortality rate of only 4% and severe comorbidities as the primary cause of death. COVID-19 severity and mortality were similar before and during the Omicron era. High CIRS-scores ( P < 0.02) and thrombocytopenia ( P < 0.01) were more frequent in patients with severe/critical disease. In real-world data, most venetoclax treated patients presented with mild COVID-19. Hospitalization and mortality rates were low compared to data of general CLL populations. Our data indicate that venetoclax was a safe treatment option for CLL patients during the pandemic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
- Department of Infectious Diseases, Zealand University Hospital, Roskilde, Denmark.
- Department of Clinical Microbiology, Zealand University Hospital, Slagelse, Denmark.
- Department of Hematology, Zealand University Hospital, Roskilde, Denmark. lmpn@regionsjaelland.dk.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. lmpn@regionsjaelland.dk.
Förderung
- Copenhagen University
Zitieren
APA
Thau, S., Poulsen, C. B., Brieghel, C., Larsen, M. K., Wiese, L., Nielsen, X. C., & Pedersen, L. M. (2024). COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05738-4
Vancouver
Thau S, Poulsen CB, Brieghel C, Larsen MK, Wiese L, Nielsen XC, et al. COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05738-4
BibTeX
@article{Thau2024,
author = {Thau, Sophie and Poulsen, Christian Bjørn and Brieghel, Christian and Larsen, Morten Kranker and Wiese, Lothar and Nielsen, Xiaohui Chen and Pedersen, Lars Møller},
title = {COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05738-4}
}
EUVIMED